Combination chemotherapy of L1210 leukemia with platinum compounds and cyclophosphamide plus other selected antineoplastic agents.
Six antitumor platinum compounds were used in combination with cyclophosphamide plut 1 of 7 other antitumor drugs for treatment of L1210 leukemia in B6D2F [C57BL/6 X DMA/2) F] mice. Data obtained from each three-agent regimen were compared with those obtained after administration of each compound alone and each appropriate two-agent combination. No cure (greater than 60-day survival) was obtained with any compound used alone. Combination of cyclophosphamide with a platinum compound (Pt+CY) yielded a collective cure rate of 193/420, and the addition of a third cure rate to 290/420 (P less than 0.001). Certain regimens produced 100% cure rates. The most effective drugs when used in combination with PT+CY were cytosine arabinoside, 5-fluorouracil, hydroxyurea, and Yoshi-864. Adriamycin, methotrexate, and vincristine were less effective at the doses used. Toxicity, as evidenced by maximum weight loss, was slightly greater with the three-agent combinations than with the Pt+CY regimens.
D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000627:therapeutic use; D007939:Leukemia L1210 / Q000188:drug therapy*; D008698:Mesylates / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010984:Platinum / Q000627:therapeutic use*; D011437:Propylamines / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D008698:Mesylates; D009942:Organometallic Compounds; D011437:Propylamines; D003561:Cytarabine; D010984:Platinum; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate